Guadecitabine and Atezolizumab in Treating Patients With Advanced Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia That Is Refractory or Relapsed
Key claim: A phase I/II trial is evaluating the safety, optimal dosing, and efficacy of guadecitabine combined with atezolizumab in patients with relapsed or refractory myelodysplastic syndrome or chronic myelomonocytic leukemia.
Abstract
This phase I/II trial studies the side effects and best dose of guadecitabine when given together with atezolizumab and to see how well they work in treating patients with myelodysplastic syndrome or chronic myelomonocytic leukemia that has spread to other places in the body and has come back or does not respond to treatment. Guadecitabine may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as atezolizumab, may interfere with the ability of cancer cells to grow and spread. Giving guadecitabine and atezolizumab may work better in treating patients with myelodysplastic syndrome or chronic myelomonocytic leukemia.
Why this matters
Refractory/relapsed CMML and MDS/MPN overlap disease have few prospective therapeutic options, and prior checkpoint inhibitor experience in myeloid malignancies has been disappointing as monotherapy. Pairing guadecitabine — a next-generation hypomethylating agent designed for prolonged decitabine exposure — with atezolizumab tests the epigenetic priming hypothesis, in which HMA-induced viral mimicry and antigen presentation may sensitize myeloid clones to PD-L1 blockade. Subtype-specific readouts will help clarify whether CMML’s monocyte-rich, inflammatory biology responds differently to checkpoint inhibition than other MDS/MPN overlap entities.